Frank Kung, Ph.D., M.B.A., is the Co-Founder and Managing Partner of Vivo Capital. See sector focus and contact routes.
Frank Kung, Ph.D., M.B.A., is the Co-Founder and Managing Partner of Vivo Capital, a healthcare-focused venture capital firm he established in Palo Alto, CA in 1996. The firm invests across public and private markets in the healthcare and biotechnology sectors, operating globally with a multi-stage approach spanning venture, private equity, and public equities. While specific check sizes and lead/follow behavior for Kung individually are not publicly detailed, Vivo Capital’s latest tracked deal was a $103.0M Series B investment in Kinaset Therapeutics. Notable portfolio companies include Medeor Therapeutics, Sagent Pharmaceuticals, and Kinaset Therapeutics, with Kung serving on the boards of Medeor and Sagent. Kung holds a doctorate and MBA from UC Berkeley and previously co-founded Genelabs Technologies and Cetus Corp, grounding his investment approach in deep biotech operational experience. He has not published distinctive public writing or a widely cited investment thesis beyond Vivo’s stated focus on healthcare innovation across the lifecycle.
Every field above is read from the StartupFundraising investor directory — disclosed location, recorded investments and stated focus — and re-checked as filings arrive. Founders pair it with investors in Palo Alto when building a target list.
Investors like Frank Kung · Full investor directory · Investor access · Company funding database